Q3 EPS Estimates for electroCore Lifted by HC Wainwright

electroCore, Inc. (NASDAQ:ECORFree Report) – Research analysts at HC Wainwright increased their Q3 2026 earnings estimates for shares of electroCore in a report released on Friday, August 7th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their previous forecast of ($0.26). The consensus estimate for electroCore’s current full-year earnings is ($1.48) per share. HC Wainwright also issued estimates for electroCore’s Q4 2026 earnings at ($0.19) EPS, FY2026 earnings at ($1.34) EPS, Q1 2027 earnings at ($0.22) EPS, Q2 2027 earnings at ($0.30) EPS, Q3 2027 earnings at ($0.17) EPS, Q4 2027 earnings at ($0.11) EPS, FY2027 earnings at ($0.81) EPS, FY2028 earnings at ($0.39) EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $0.65 EPS.

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of electroCore in a research note on Wednesday, June 24th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $18.00.

Check Out Our Latest Stock Analysis on ECOR

electroCore Stock Performance

Shares of ECOR opened at $8.96 on Tuesday. The business’s fifty day moving average is $7.67 and its 200-day moving average is $7.01. The firm has a market cap of $80.82 million, a price-to-earnings ratio of -5.40 and a beta of 0.93. electroCore has a 52-week low of $4.16 and a 52-week high of $10.49.

electroCore (NASDAQ:ECORGet Free Report) last issued its quarterly earnings results on Thursday, August 6th. The company reported ($0.33) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.09. The company had revenue of $9.45 million during the quarter, compared to the consensus estimate of $9.49 million. electroCore had a negative net margin of 39.96% and a negative return on equity of 1,956.38%.

Insiders Place Their Bets

In other news, Director Thomas J. Errico bought 9,992 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was acquired at an average price of $5.99 per share, with a total value of $59,852.08. Following the transaction, the director owned 360,071 shares of the company’s stock, valued at $2,156,825.29. This trade represents a 2.85% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO Joshua S. Lev sold 6,667 shares of the stock in a transaction on Thursday, May 28th. The stock was sold at an average price of $9.00, for a total transaction of $60,003.00. Following the sale, the chief financial officer owned 84,889 shares of the company’s stock, valued at approximately $764,001. This trade represents a 7.28% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. 7.80% of the stock is currently owned by insiders.

Institutional Trading of electroCore

A number of institutional investors have recently bought and sold shares of ECOR. NewEdge Advisors LLC raised its position in shares of electroCore by 857.9% in the 1st quarter. NewEdge Advisors LLC now owns 161,955 shares of the company’s stock worth $1,083,000 after acquiring an additional 145,047 shares in the last quarter. Tejara Capital Ltd acquired a new stake in shares of electroCore in the 4th quarter valued at about $450,000. International Assets Investment Management LLC increased its position in electroCore by 15.2% in the 4th quarter. International Assets Investment Management LLC now owns 88,720 shares of the company’s stock valued at $398,000 after buying an additional 11,700 shares in the last quarter. DRW Securities LLC bought a new stake in electroCore in the 4th quarter valued at about $264,000. Finally, Jane Street Group LLC increased its holdings in shares of electroCore by 114.4% during the first quarter. Jane Street Group LLC now owns 36,726 shares of the company’s stock valued at $246,000 after acquiring an additional 19,599 shares in the last quarter. Institutional investors own 26.74% of the company’s stock.

electroCore News Roundup

Here are the key news stories impacting electroCore this week:

  • Positive Sentiment: HC Wainwright raised its fiscal 2026 EPS forecast to -$1.34 from -$1.49, while Brookline Capital Markets increased its estimate to -$1.39 from -$1.43. Both firms also made slightly less pessimistic forecasts for third-quarter 2026 earnings.
  • Positive Sentiment: HC Wainwright improved its estimates for the first and second quarters of 2027, forecasting losses of $0.22 and $0.30 per share, respectively, compared with prior estimates of $0.37 per share losses for both periods.
  • Neutral Sentiment: Despite the upward revisions, analysts still expect substantial losses: HC Wainwright projects fiscal 2027 EPS of -$0.81, versus the current-year consensus estimate of -$1.48. The firm’s longer-range forecasts anticipate a return to profitability in 2029, followed by $0.65 EPS in 2030.
  • Negative Sentiment: HC Wainwright cut its fiscal 2027 EPS forecast to -$0.81 from -$0.67 and reduced its fiscal 2028 estimate to -$0.39 from -$0.13, extending the expected period of losses.
  • Negative Sentiment: Long-term estimates were sharply lowered: fiscal 2029 EPS was reduced to $0.15 from $0.36, and fiscal 2030 EPS to $0.65 from $0.90. HC Wainwright also lowered its fourth-quarter 2026 and third-quarter 2027 forecasts.

electroCore Company Profile

(Get Free Report)

electroCore, Inc is a commercial-stage bioelectronic medicine company headquartered in Rockaway, New Jersey. The company specializes in the development and commercialization of non-invasive vagus nerve stimulation (nVNS) therapies designed to address a variety of neurological and inflammatory conditions. Established in 2006, electroCore has focused its efforts on translating neuromodulation science into a compact, patient-administered treatment device.

The company’s lead product, gammaCore®, is a handheld, battery-powered device that delivers nVNS through the skin to the cervical branch of the vagus nerve.

Read More

Earnings History and Estimates for electroCore (NASDAQ:ECOR)

Receive News & Ratings for electroCore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for electroCore and related companies with MarketBeat.com's FREE daily email newsletter.